关键信息
-
基因名
MAGEA2B
- 应用
-
别名
MAGEA2; MAGE2; MAGEA2A;; MAGEA2B; MAGE2; MAGEA2; Melanoma-associated antigen 2; Cancer/testis antigen 1.2; CT1.2; MAGE-2 antigen
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P43356
-
表达区间
1-314aa
-
氨基酸序列
MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQQTASSSSTLVEVTL GEVPAADSPSPPHSPQGASSFSTTINYTLWRQSDEGSSNQEEEGPRMFPD LESEFQAAISRKMVELVHFLLLKYQAREPVTKAEMLESVLRNCQDFFPVI FSKASEYLQLVFGIEVVEVVPISHLYILVTCLGLSYDGLLGDNQVMPKTG LLIIVLAIIAIEGDCAPEEKIWEELSMLEVFEGREDSVFAHPRKLLMQDL VQENYLEYRQVPGSDPACYEFLWGPRALIETSYVKVLHHTLKIGGEPHIS YPPLHERALREGEE
-
分子量
35 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
MAGEA2B is a member of the melanoma-associated antigens (MAGE) family, which are known for their roles in cancer biology, particularly in melanoma and other tumors. These proteins are characterized by their ability to elicit specific immune responses, making them attractive targets for cancer immunotherapy. Research has shown that MAGEA2B is selectively expressed in various malignancies and not in normal tissues, highlighting its potential as a tumor-associated antigen. The study of MAGEA2B recombinant proteins focuses on understanding its structure, function, and interaction with immune cells, paving the way for the development of MAGEA2B-targeted therapies. Recent advancements in recombinant protein technologies allow for the production and characterization of MAGEA2B, facilitating the exploration of its immunogenic properties. These studies aim to harness the immune system's ability to recognize and attack cancer cells expressing MAGEA2B, contributing to the design of personalized cancer vaccines and adoptive T cell therapies. As the field of cancer immunotherapy continues to evolve, MAGEA2B represents a promising candidate for novel therapeutic strategies, with the potential to improve patient outcomes and enhance the efficacy of existing treatment modalities. Understanding the biological role of MAGEA2B will also provide insights into tumor biology and the development of new diagnostic tools, reinforcing its significance in oncological research.
